MRSA Bloodstream Infections: Heteroresistance Raises Mortality Risk by 2.5 Times
Analysis of 842 Patients Over 15 Years
New Predictive Criteria Proposed Using "PAP-AUC" Test
In patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections, the risk of death within 90 days increases by up to 2.5 times if the bacteria exhibit "heteroresistance" to vancomycin, the standard treatment. The infection also tends to persist longer and the risk of recurrence rises significantly, providing evidence that antibiotic strategies should be adjusted from the early stages of treatment.
On January 28, Hallym University Sacred Heart Hospital announced that a research team led by Yonggyun Kim, Professor of Infectious Diseases at Hallym University Sacred Heart Hospital, and Yangsoo Kim, Professor of Infectious Diseases at Seoul Asan Medical Center, tracked and analyzed 842 domestic MRSA bloodstream infection patients over 15 years and confirmed these findings. The study was conducted as an international collaboration with Uppsala University in Sweden. The results were published in the December issue of the international journal Nature Communications.
MRSA is a pathogen resistant to common penicillin or cephalosporin antibiotics and has been designated by the World Health Organization (WHO) as a priority pathogen for antibiotic resistance. When it spreads throughout the body via the bloodstream, it can lead to sepsis or organ failure, resulting in a high fatality rate.
Currently, vancomycin is the most widely used standard treatment for MRSA bloodstream infections. However, in clinical practice, there have been ongoing reports of treatment failure cases where the bacteria are not eradicated or fever persists even after vancomycin administration.
The research team focused on "heteroresistance," a phenomenon in which only some bacteria survive antibiotic treatment, as a cause of treatment failure. MRSA strains that show heteroresistance to vancomycin are referred to as "hVISA," and are not easily distinguished by standard tests.
The study found that when vancomycin treatment was continued in hVISA patients, the risk of death within 90 days was more than 2.5 times higher than in general MRSA patients. The duration of MRSA bloodstream infection was also an average of 1.8 days longer, and the recurrence rate within 90 days after treatment was about five times higher.
Through additional analysis, the research team confirmed that when the "PAP-AUC" test value used to identify hVISA exceeds 0.65, the risk of death increases significantly. This provides a criterion for considering switching to antibiotics other than vancomycin or combination therapy from the early stages of treatment.
Professor Yonggyun Kim stated, "We have confirmed with large-scale patient data that partial resistance of MRSA, which is easily missed by standard tests, actually leads to increased treatment failure and mortality risk in clinical settings. The PAP-AUC criterion can serve as a practical indicator for determining initial treatment strategies."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.